Smith & Nephew : +Nephew Meet the Management presentation - 16 December 2021

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue.

We exist to restore people's bodies and their self-belief by using technology to take the limits off living.

We call this purpose 'Life Unlimited'.

Meet the Management 2021

Roland Diggelmann

Chief Executive Officer

Anne-Francoise Nesmes

Chief Financial Officer

Forward looking statements and non-IFRS measures

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. The terms 'Group' and 'Smith+Nephew' are used for convenience to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

Certain items included in 'trading results', such as trading profit, trading profit margin, tax rate on trading results, trading cash flow, trading profit to cash conversion ratio, EPSA, leverage ratio, and underlying growth are non-IFRS financial measures. The non-IFRS financial measures in this announcement are explained and reconciled to the most directly comparable financial measure prepared in accordance with IFRS in our Second Quarter and Half Year 2021

Results announcement dated 29 July 2021.	2

Agenda

Time (GMT)	Session	Presentation

		Strategy for Growth
12.30 - 13.30	Presentation	Roland Diggelmann, Chief Executive Officer
Anne-FrancoiseNesmes, Chief Financial Officer
Break		CEO/CFO Q&A
		Roland Diggelmann, Chief Executive Officer
		Anne-FrancoiseNesmes, Chief Financial Officer
13.45 - 14.30	Breakout 1	Orthopaedics
		Brad Cannon, President, Orthopaedics, Sports Medicine and ENT
14.35 - 15.20	Breakout 2	Randy Kilburn, EVP & GM Reconstruction, Robotics and Digital
		Craig Gaffin, SVP & GM Trauma & Extremities, US Commercial
Break		Advanced Wound Management
15.35 - 16.20	Breakout 3	Simon Fraser, President Advanced Wound Management
and Global Commercial Operations
		Cathy Dalene, SVP Global Strategic Marketing Advanced
16.25 - 17.10	Breakout 4	Wound Management
Sports Medicine & ENT
		Scott Schaffner, EVP & GM Sports Medicine
17.10	Close	Meghan Mavity, VP & GM Global ENT

3

Strategy for Growth

An inflection point - transforming to a structurally higher growth company

Innovation led	Productivity &
•	Existing strong portfolio	Commercial
Excellence driven
•	Pipeline of disruptive
	technology	•	Manufacturing and supply
•	Establish engines for		optimization
	organic and external	•	Sustain strong profitable
	opportunities		growth in AWM & Sports
			(60% of the business)
		• Re-establish momentum
			and growth in Orthopaedics

Financial performance commitment

• Consistent 4-6% organic revenue growth
• Rebuild trading margin
• • Maintain higher R&D investment
  • At or above 21% by 2024
  • Margin improving thereafter
• TSR focus: earnings growth, cashflow & ROIC

Capital Allocation discipline

• Invest in
• • Innovation
  • Bolt-onacquisitions
• Maintain progressive dividend policy & investment grade credit metrics
• Commence regular buyback (c.$250m-$300m planned in 2022)

4

Solid long-term demand drivers intact

Prevalence

Growth in lifestyle related health conditions

Emerging markets Economic development driving healthcare access

Lifestyle

Higher levels of physical activity later in life

Decentralised care

Shift to outpatient settings accelerated by COVID

Demographics

More patients from better life expectancy

5